An analog refers to something that is “analogous” or similar to something else. Therefore, “insulin” analogs are analogs that have been designed to mimic the body’s natural pattern of insulin release. These synthetic-made insulins are called analogs of human insulin. However, they have minor structural or amino acid changes that give them special desirable characteristics when injected under the skin. Once absorbed, they act on cells like human insulin, but are absorbed from fatty tissue more predictably.
Rapid-Acting Insulin Analog
The fastest-working insulins are referred to as rapid-acting insulin.
Long-Acting Insulin Analog
Insulin Glargine (Lantus®)
As many of the insulin analogs have patent expiration or imminent expiration, there is increased focus on developing biosimilars for these analogs. KRISHGEN is happy to announce assays developed for supporting development and research.
Aspart ELISA | Lispro ELISA | Glargine ELISA | Anti Aspart ELISA | Anti Lispro ELISA | Anti Glargine ELISA
View Product Flyer | White Paper on Insulin Analog Assays
Immunogenicity assays are integral to biologic drug development. Biotherapeutics can induce an immune response in the body, leading to the development of anti-drug antibodies (ADAs) which can potentially threaten patient safety. Assessment of ADAs, which may inhibit the biologic activity of the drug, form a fundamental part of immunogenicity testing.
Immunogenicity assays can be challenging due to interferences originating from the sample matrix, drug interference or target interference. The requirement is for extensive data with demonstration of high sensitive and precision. Our immunogenicity assay kits utilize a multi-tiered approach to measure ADAs through our experience in the development and validation of qualitative and quasi-quantitative immunoassays.
Products Offered: Anti-Glargine ELISA | Anti-Glargine Development ELISA
View Product Flyer | White Paper on Insulin Analog Immunogenicity
Showing all 2 results